1Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, No. 301, Yanchangzhong Road, Shanghai 200072, China 2Thyroid Institute, Tongji University School of Medicine, No. 301, Yanchangzhong Road, Shanghai 200072, China 3Central Ultrasound Department, Klinikum Siloah, KRH, Roesebeckstrasse 15, 30449 Hannover, Germany 4Department of Radiology, Tho...

: Ente Nuove tecnologie Energia Ambiente (ENEA) Section of Toxicology and Biomedical Sciences, Via Anguillarese, 301 00060 S. Maria di Galeria (Rome) Italy. : Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th street, 19107 Philadelphia, PA, USA. :To whom correspondence should be addressed at: Ente Nuove tecnologie Energia Ambiente (ENEA) Section of Toxicology and Biomedical Scie...

The Food and Drug Administration (FDA) is announcing a public meeting to discuss the development, assessment, and regulation of abuse-deterrent formulations of opioid medications. The meeting will focus on scientific and technical issues related to the development and in vitro assessment of these products, as well as FDA’s approach towards assessing the benefits and risks of all opioid medicati...

www.sciencemag.org (this information is current as of May 27, 2008 ): The following resources related to this article are available online at http://www.sciencemag.org/cgi/content/full/301/5634/829 version of this article at: including high-resolution figures, can be found in the online Updated information and services, http://www.sciencemag.org/cgi/content/full/301/5634/829#otherarticles , 14 ...

Entinostat, a class I-selective histone deacetylase inhibitor, has shown promising activity in ENCORE 301, a randomized, placebo-controlled, phase II trial of exemestane with or without entinostat in women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on a nonsteroidal aromatase inhibitor. ENCORE 301 showed an 8.3-mo improvement in median overall surv...